Loading video...

Video Failed to Load

Go Home

Dr. Patrick Soon-Shiong: We've ignored a key CBC metric for 75 years—Absolute Lymphocyte Count (ALC)—your body's count of cancer-fighting NK cells, T cells, memory T cells, B cells, dendritic cells (collectively lymphocytes). Low ALC ( 1,500–1,800 for immune "store." Chemo/radiation/COVID wipe it out—yet until now, nothing to fix it....

newstart_2024's profile picture

Camus

462,705 subscribers

68,193 views • 8 months ago •via X (Twitter)

Health & WellnessScience & Technology
LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

10 Headlines They Don’t Want You to Hear Today #10 – Entrepreneur and health innovator Dr. Patrick Soon-Shiong concludes that the disease of cancer is merely a symptom of a collapsed immune system. According to Soon-Shiong, the key marker that’s been overlooked for decades is your Absolute Lymphocyte Count (ALC). He says when it drops below 1000 cells per microliter — a condition called lymphopenia — your body is left defenseless against infection, cancer growth, and metastasis. And science dating back to the 1990s reveals people with lymphopenia have much worse cancer outcomes. “What ALC is, actually, is your lymphocytes and your T-cells,” he told Megyn Kelly. “And the lymphocytes and T-cells are the only cells that really matter to prevent infection, to prevent cancer, to treat the cancer, to prevent metastasis,” he explained. “[So] it’s simple and yet profound that we’ve unlocked a paradigm change where we treat the host, i.e., the immune system, rather than the disease. In fact… the root cause of cancer is the collapse of the immune system.” Hat Tip: Camus SEE THE NEXT 9 STORIES BELOW
1:56

10 Headlines They Don’t Want You to Hear Today #10 – Entrepreneur and health innovator Dr. Patrick Soon-Shiong concludes that the disease of cancer is merely a symptom of a collapsed immune system. According to Soon-Shiong, the key marker that’s been overlooked for decades is your Absolute Lymphocyte Count (ALC). He says when it drops below 1000 cells per microliter — a condition called lymphopenia — your body is left defenseless against infection, cancer growth, and metastasis. And science dating back to the 1990s reveals people with lymphopenia have much worse cancer outcomes. “What ALC is, actually, is your lymphocytes and your T-cells,” he told Megyn Kelly. “And the lymphocytes and T-cells are the only cells that really matter to prevent infection, to prevent cancer, to treat the cancer, to prevent metastasis,” he explained. “[So] it’s simple and yet profound that we’ve unlocked a paradigm change where we treat the host, i.e., the immune system, rather than the disease. In fact… the root cause of cancer is the collapse of the immune system.” Hat Tip: Camus SEE THE NEXT 9 STORIES BELOW

The Vigilant Fox 🦊

1,120,240 views • 1 year ago

Of all the casualties in the war on cancer, the most critical have been the most ignored: your NK and T cells. As Dr. Patrick Soon-Shiong explains, while oncology has long treated the anemia and neutropenia caused by chemotherapy, it has overlooked the destruction of the very immune cells that fight cancer. For 35 years, there was no treatment for this catastrophic side effect. That era is over. Dr. Soon-Shiong announces ANKTIVA, the first FDA-approved therapy proven to activate NK cells, T cells, and memory T cells. The result? Documented complete responses in bladder cancer patients, free of disease for over nine years. This breakthrough shatters a long-standing medical blind spot. Whether from chemo, radiation, or a severe viral infection, the body's primary defense is often wiped out. ANKTIVA represents a paradigm shift—from solely attacking disease to actively re-arming the patient's own immune system. The future of medicine is not just fighting the enemy, but empowering the army within.
3:35

Of all the casualties in the war on cancer, the most critical have been the most ignored: your NK and T cells. As Dr. Patrick Soon-Shiong explains, while oncology has long treated the anemia and neutropenia caused by chemotherapy, it has overlooked the destruction of the very immune cells that fight cancer. For 35 years, there was no treatment for this catastrophic side effect. That era is over. Dr. Soon-Shiong announces ANKTIVA, the first FDA-approved therapy proven to activate NK cells, T cells, and memory T cells. The result? Documented complete responses in bladder cancer patients, free of disease for over nine years. This breakthrough shatters a long-standing medical blind spot. Whether from chemo, radiation, or a severe viral infection, the body's primary defense is often wiped out. ANKTIVA represents a paradigm shift—from solely attacking disease to actively re-arming the patient's own immune system. The future of medicine is not just fighting the enemy, but empowering the army within.

Camus

55,260 views • 11 months ago

Dr. Patrick Soon-Shiong reveals the "missing link" in cancer medicine that’s been hiding in plain sight for 450 million years of evolution: Natural Killer (NK) cells — your body’s built-in cancer assassins. Just like red blood cells prevent death from lack of oxygen, NK cells (and T cells) are designed to destroy cancer cells. Yet we’ve ignored them for most of medical history. In 2012, the National Cancer Institute reviewed 240 molecules and declared IL-15 the single most important one for curing cancer — because it supercharges NK cells and T cells. The problem? No one could deliver IL-15 safely and effectively… until Anktiva. 1:51 clip embedded — his passionate delivery makes the breakthrough feel like the missing piece we’ve overlooked for decades. Cancer isn’t just about killing tumors. It’s about waking up the immune system we were born with.
1:51

Dr. Patrick Soon-Shiong reveals the "missing link" in cancer medicine that’s been hiding in plain sight for 450 million years of evolution: Natural Killer (NK) cells — your body’s built-in cancer assassins. Just like red blood cells prevent death from lack of oxygen, NK cells (and T cells) are designed to destroy cancer cells. Yet we’ve ignored them for most of medical history. In 2012, the National Cancer Institute reviewed 240 molecules and declared IL-15 the single most important one for curing cancer — because it supercharges NK cells and T cells. The problem? No one could deliver IL-15 safely and effectively… until Anktiva. 1:51 clip embedded — his passionate delivery makes the breakthrough feel like the missing piece we’ve overlooked for decades. Cancer isn’t just about killing tumors. It’s about waking up the immune system we were born with.

Camus

38,499 views • 8 months ago

DR. PATRICK SOON-SHIONG: So Drew, I'd like you to test this with your oncology friends and say, when you do a CBC, which is a standard blood test, what do you look for to treat your patient? "Well, we look for anemia and we look for neutropenia." "Do you look for lymphocyte count"? No, Why? We don't bother about it because there's no treatment for that. It turns out the only thing that protects your body against cancer is your lymphocytes, meaning the NK cells and T cells. And there was no treatment for that for 35 years until last year, 2024, when it got approved, Anktiva.
0:37

DR. PATRICK SOON-SHIONG: So Drew, I'd like you to test this with your oncology friends and say, when you do a CBC, which is a standard blood test, what do you look for to treat your patient? "Well, we look for anemia and we look for neutropenia." "Do you look for lymphocyte count"? No, Why? We don't bother about it because there's no treatment for that. It turns out the only thing that protects your body against cancer is your lymphocytes, meaning the NK cells and T cells. And there was no treatment for that for 35 years until last year, 2024, when it got approved, Anktiva.

Dr. Kash Sarabi

42,273 views • 1 year ago

🚨ImmunityBio’s Anktiva: A New FDA-Approved Immunotherapy for certain bladder cancer. They are also developing treatments that may reduce the need for strong chemo, for blood cancer, lung cancer, brain cancer, and more. Broader approvals may take time. Someone call the President and fast-track this. Dr. Pat Soon-Shiong leads development beyond typical biotech efforts. Most cancer medicines, like chemotherapy, work by poisoning fast-growing cells to kill the cancer. This also hurts healthy cells, causing side effects like hair loss and weakness. Anktiva is different. It is an immunotherapy that wakes up your body’s own immune cells; natural killer cells and T cells to hunt and destroy cancer cells themselves. It acts like a booster shot for your immune system, using a protein called IL-15 to make these cells multiply and remember how to fight cancer long-term. ImmunityBio is different from most companies because of 3 big unique things: 1. They wake up 3 kinds of fighter cells at the same time: • NK cells (natural killers) • CD8 T cells (main attackers) • CD4 T cells (helpers) These three work together like a basketball team. This makes the body remember the cancer for a long time (maybe years). 2. They have a special cell line called NK-92. → It’s like buying frozen pizza instead of making dough from scratch every time. Doctors can just thaw it and give it to any patient. No need to take cells from the sick kid, customize them, and make them super weak with hospital chemo (that’s what normal CAR-T does). 3. Their medicine Anktiva gives a long, steady boost to the immune cells. Older drugs (like IL-2) gave a short, crazy boost that made people very sick. Anktiva is seems safer, so far. Exciting to follow the development. Interview: Chris Cuomo (NewsNation) — “Killing Cancer”
8:29

🚨ImmunityBio’s Anktiva: A New FDA-Approved Immunotherapy for certain bladder cancer. They are also developing treatments that may reduce the need for strong chemo, for blood cancer, lung cancer, brain cancer, and more. Broader approvals may take time. Someone call the President and fast-track this. Dr. Pat Soon-Shiong leads development beyond typical biotech efforts. Most cancer medicines, like chemotherapy, work by poisoning fast-growing cells to kill the cancer. This also hurts healthy cells, causing side effects like hair loss and weakness. Anktiva is different. It is an immunotherapy that wakes up your body’s own immune cells; natural killer cells and T cells to hunt and destroy cancer cells themselves. It acts like a booster shot for your immune system, using a protein called IL-15 to make these cells multiply and remember how to fight cancer long-term. ImmunityBio is different from most companies because of 3 big unique things: 1. They wake up 3 kinds of fighter cells at the same time: • NK cells (natural killers) • CD8 T cells (main attackers) • CD4 T cells (helpers) These three work together like a basketball team. This makes the body remember the cancer for a long time (maybe years). 2. They have a special cell line called NK-92. → It’s like buying frozen pizza instead of making dough from scratch every time. Doctors can just thaw it and give it to any patient. No need to take cells from the sick kid, customize them, and make them super weak with hospital chemo (that’s what normal CAR-T does). 3. Their medicine Anktiva gives a long, steady boost to the immune cells. Older drugs (like IL-2) gave a short, crazy boost that made people very sick. Anktiva is seems safer, so far. Exciting to follow the development. Interview: Chris Cuomo (NewsNation) — “Killing Cancer”

Black Panther Capital

40,249 views • 8 months ago

Dr. Patrick Soon-Shiong: "The Disease of Cancer is a Symptom. The Root Cause is a Collapse of the Immune System." A startling discovery is changing everything we know about cancer and longevity. The key isn't found in a new drug, but in a simple, often-ignored number on your blood test: the Absolute Lymphocyte Count (ALC). As Dr. Soon-Shiong explains, if your ALC drops below 1000 cells/μL (a condition known as lymphopenia), the statistical risk of a shortened lifespan increases dramatically. This isn't a new theory; it's a clinical fact supported by hundreds of publications spanning decades. The data is undeniable: whether for breast, lung, pancreatic, or any other cancer, lymphopenia consistently predicts a significantly worse outcome. The reason is profound in its simplicity. Your ALC is your immune army. These lymphocytes and T-cells are your body's only dedicated soldiers to fight infection, prevent cancer, and stop metastasis. A low count means the front line is defenseless. We have been treating the symptom—the tumor—while ignoring the root cause. The disease is not the cancer; the cancer is a symptom of a failed immune system. This is a fundamental paradigm shift. The future of medicine lies in treating the host, not just the disease. By restoring immune competence, we don't just attack one illness; we empower the body to defend itself against many. It is a simple, yet profound, unlocking of a new era in healthcare.
1:56

Dr. Patrick Soon-Shiong: "The Disease of Cancer is a Symptom. The Root Cause is a Collapse of the Immune System." A startling discovery is changing everything we know about cancer and longevity. The key isn't found in a new drug, but in a simple, often-ignored number on your blood test: the Absolute Lymphocyte Count (ALC). As Dr. Soon-Shiong explains, if your ALC drops below 1000 cells/μL (a condition known as lymphopenia), the statistical risk of a shortened lifespan increases dramatically. This isn't a new theory; it's a clinical fact supported by hundreds of publications spanning decades. The data is undeniable: whether for breast, lung, pancreatic, or any other cancer, lymphopenia consistently predicts a significantly worse outcome. The reason is profound in its simplicity. Your ALC is your immune army. These lymphocytes and T-cells are your body's only dedicated soldiers to fight infection, prevent cancer, and stop metastasis. A low count means the front line is defenseless. We have been treating the symptom—the tumor—while ignoring the root cause. The disease is not the cancer; the cancer is a symptom of a failed immune system. This is a fundamental paradigm shift. The future of medicine lies in treating the host, not just the disease. By restoring immune competence, we don't just attack one illness; we empower the body to defend itself against many. It is a simple, yet profound, unlocking of a new era in healthcare.

Camus

281,907 views • 1 year ago

Dr. Patrick Soon-Shiong challenges the core of cancer treatment: Are we fighting cancer incorrectly? In a compelling interview, he explains how lymphocytes—Natural Killer cells and T-cells—are the body’s critical defenders, essential for defeating cancer, infections, and sepsis. Yet, modern medicine has been undermining them. Lymphocytes are the body’s elite immune cells. Natural Killer cells and T-cells are uniquely equipped to destroy cancer cells and are vital for combating life-threatening infections and sepsis. Dr. Soon-Shiong describes them as the foundation for long life and survival. But there’s a problem. Conventional cancer treatments—chemotherapy, radiation, and steroids—destroy these lymphocytes, causing lymphopenia, a depletion akin to anemia but for the immune system. For decades, medicine has inadvertently targeted the very cells needed to win the war against cancer. A breakthrough molecule, IL-15, changes everything. This protein, produced naturally in the body, acts as a master switch to activate and proliferate lymphocytes, enabling them to eradicate cancer and infections. For the first time, medicine can harness this mechanism through BioShield. BioShield leverages IL-15 to empower lymphocytes, marking a revolutionary shift in treatment. Unlike chemotherapy, which Dr. Soon-Shiong likens to a nuclear bomb that devastates the body, IL-15 strengthens the immune system to fight smarter. Why have traditional treatments fallen short? Chemotherapy and radiation may shrink tumors, achieving what’s called a response, but at a steep cost. They deplete lymphocytes, weaken immunity, and allow resistant cancer cells to hide and later return as metastases. Dr. Soon-Shiong raises a provocative question: Have treatments induced incurability? The focus on response rates and progression-free survival, standard metrics for drug approval, misses the true goal: overall survival with high quality of life. Current therapies, often dosed at the maximum tolerated level, prioritize short-term wins over long-term health. Dr. Soon-Shiong critiques this approach, suggesting that medicine has been winning battles but losing wars. By destroying lymphocytes, treatments may shrink tumors temporarily but leave patients vulnerable to relapse. The regulatory system, he argues, has incentivized flawed endpoints. BioShield’s IL-15 therapy offers hope, activating the body’s natural defenses without obliterating them. This could redefine cancer care, prioritizing immune strength and long-term survival over transient tumor shrinkage. Dr. Soon-Shiong’s vision challenges 50 years of oncology dogma. Is it possible that medicine has misunderstood cancer treatment for decades? Dr. Soon-Shiong’s insights demand reflection. By protecting and activating lymphocytes, we might unlock the body’s true potential to heal.
4:13

Dr. Patrick Soon-Shiong challenges the core of cancer treatment: Are we fighting cancer incorrectly? In a compelling interview, he explains how lymphocytes—Natural Killer cells and T-cells—are the body’s critical defenders, essential for defeating cancer, infections, and sepsis. Yet, modern medicine has been undermining them. Lymphocytes are the body’s elite immune cells. Natural Killer cells and T-cells are uniquely equipped to destroy cancer cells and are vital for combating life-threatening infections and sepsis. Dr. Soon-Shiong describes them as the foundation for long life and survival. But there’s a problem. Conventional cancer treatments—chemotherapy, radiation, and steroids—destroy these lymphocytes, causing lymphopenia, a depletion akin to anemia but for the immune system. For decades, medicine has inadvertently targeted the very cells needed to win the war against cancer. A breakthrough molecule, IL-15, changes everything. This protein, produced naturally in the body, acts as a master switch to activate and proliferate lymphocytes, enabling them to eradicate cancer and infections. For the first time, medicine can harness this mechanism through BioShield. BioShield leverages IL-15 to empower lymphocytes, marking a revolutionary shift in treatment. Unlike chemotherapy, which Dr. Soon-Shiong likens to a nuclear bomb that devastates the body, IL-15 strengthens the immune system to fight smarter. Why have traditional treatments fallen short? Chemotherapy and radiation may shrink tumors, achieving what’s called a response, but at a steep cost. They deplete lymphocytes, weaken immunity, and allow resistant cancer cells to hide and later return as metastases. Dr. Soon-Shiong raises a provocative question: Have treatments induced incurability? The focus on response rates and progression-free survival, standard metrics for drug approval, misses the true goal: overall survival with high quality of life. Current therapies, often dosed at the maximum tolerated level, prioritize short-term wins over long-term health. Dr. Soon-Shiong critiques this approach, suggesting that medicine has been winning battles but losing wars. By destroying lymphocytes, treatments may shrink tumors temporarily but leave patients vulnerable to relapse. The regulatory system, he argues, has incentivized flawed endpoints. BioShield’s IL-15 therapy offers hope, activating the body’s natural defenses without obliterating them. This could redefine cancer care, prioritizing immune strength and long-term survival over transient tumor shrinkage. Dr. Soon-Shiong’s vision challenges 50 years of oncology dogma. Is it possible that medicine has misunderstood cancer treatment for decades? Dr. Soon-Shiong’s insights demand reflection. By protecting and activating lymphocytes, we might unlock the body’s true potential to heal.

Camus

48,343 views • 1 year ago

Dr. Patrick Soon-Shiong, a pioneering surgeon and scientist, reveals a shocking truth about chemotherapy, immunity, and why we’ve been fighting cancer the wrong way for decades. Here’s what’s simple—and profound: When you undergo chemotherapy, the first casualty is your red blood cells, leading to anemia (treated with Epogen). Next, it wipes out neutrophils, leaving you vulnerable to infection (treated with Neupogen). But the most devastating effect? It destroys your NK and T cells—your body’s elite cancer-fighting forces. Think about that: The very treatment meant to kill cancer also annihilates the only cells that can actually protect you from it. For 35 years, medicine has ignored this paradox. We replace red blood cells and neutrophils—but not the lymphocytes that matter most. The result? A weakened immune system, vulnerable to relapse and secondary cancers. Now, consider long COVID. The virus is cunning—it targets the same NK and T cells, crippling immunity. The parallel is undeniable: Weakening these cells leaves the body defenseless, whether from chemo or chronic infection. Dr. Soon-Shiong’s message is clear: "We’ve been treating cancer wrong." The future lies in restoring immune function, not just attacking tumors. The fight isn’t just against cancer or viruses—it’s for the immune system itself. And after 20 years of challenging the status quo, Dr. Soon-Shiong is leading that revolution. It’s time to rethink everything.
1:47

Dr. Patrick Soon-Shiong, a pioneering surgeon and scientist, reveals a shocking truth about chemotherapy, immunity, and why we’ve been fighting cancer the wrong way for decades. Here’s what’s simple—and profound: When you undergo chemotherapy, the first casualty is your red blood cells, leading to anemia (treated with Epogen). Next, it wipes out neutrophils, leaving you vulnerable to infection (treated with Neupogen). But the most devastating effect? It destroys your NK and T cells—your body’s elite cancer-fighting forces. Think about that: The very treatment meant to kill cancer also annihilates the only cells that can actually protect you from it. For 35 years, medicine has ignored this paradox. We replace red blood cells and neutrophils—but not the lymphocytes that matter most. The result? A weakened immune system, vulnerable to relapse and secondary cancers. Now, consider long COVID. The virus is cunning—it targets the same NK and T cells, crippling immunity. The parallel is undeniable: Weakening these cells leaves the body defenseless, whether from chemo or chronic infection. Dr. Soon-Shiong’s message is clear: "We’ve been treating cancer wrong." The future lies in restoring immune function, not just attacking tumors. The fight isn’t just against cancer or viruses—it’s for the immune system itself. And after 20 years of challenging the status quo, Dr. Soon-Shiong is leading that revolution. It’s time to rethink everything.

Camus

327,541 views • 1 year ago

Big Pharma spends billions on cancer drugs that may weaken our body’s natural defenses, but Dr. Soon-Shiong reveals a $10 test could hold the key to longevity—keeping your natural killer cells above 1,000 to fight cancer, infections, and more! Dr. Patrick Soon-Shiong unveils a groundbreaking perspective on human health, describing not an invention but an evolution in understanding the body’s defense system. For 450-460 million years, a single cell has enabled mammalian survival against infection, cancer, and trauma: the natural killer (NK) cell. This cell, he argues, forms the foundation of a unifying theory of longevity—a bold claim grounded in decades of research. Soon-Shiong critiques the conventional “whack-a-mole” approach to cancer treatment. He spent years chasing genomic mutations, only to realize that targeting one mutation often spawns another. Big Pharma, he notes, invests billions in mutation-specific drugs, chemotherapy, radiation, and checkpoint inhibitors—treatments that inadvertently suppress the very NK cells critical to life. Even therapies like EPOGEN and NEUPOGEN, designed to support chemotherapy, enable more aggressive treatments that further deplete these vital cells. The solution, he proposes, is startlingly simple: monitor the absolute lymphocyte count (ALC) via a $10 CBC test. NK cells, a subset of lymphocytes, must remain above 1,000 per microliter to maintain robust defense against cancer, infections, and sepsis. Radiation, however, often crashes this count, sometimes for over a year, leaving patients vulnerable to metastasis. A recent study highlights this “badscopal” effect, where radiation, while shrinking one tumor, may increase metastatic spread by wiping out NK cells—contrasting the long-touted “abscopal” benefit of systemic tumor reduction. Aging, viral infections, sepsis, and cancer all correlate with declining NK cell levels. Yet, Soon-Shiong emphasizes, these cells possess an innate ability to recognize and destroy transforming cells before they become cancerous. This insight shifts the paradigm from attacking disease to bolstering the body’s natural defenses. The challenge now is to rethink medical approaches. “Follow the science,” Soon-Shiong urges, advocating for data-driven strategies over entrenched agendas. By preserving NK cell counts, we may unlock the secret to long, healthy lives. This isn’t just a theory—it’s a call to transform how we fight disease.
5:08

Big Pharma spends billions on cancer drugs that may weaken our body’s natural defenses, but Dr. Soon-Shiong reveals a $10 test could hold the key to longevity—keeping your natural killer cells above 1,000 to fight cancer, infections, and more! Dr. Patrick Soon-Shiong unveils a groundbreaking perspective on human health, describing not an invention but an evolution in understanding the body’s defense system. For 450-460 million years, a single cell has enabled mammalian survival against infection, cancer, and trauma: the natural killer (NK) cell. This cell, he argues, forms the foundation of a unifying theory of longevity—a bold claim grounded in decades of research. Soon-Shiong critiques the conventional “whack-a-mole” approach to cancer treatment. He spent years chasing genomic mutations, only to realize that targeting one mutation often spawns another. Big Pharma, he notes, invests billions in mutation-specific drugs, chemotherapy, radiation, and checkpoint inhibitors—treatments that inadvertently suppress the very NK cells critical to life. Even therapies like EPOGEN and NEUPOGEN, designed to support chemotherapy, enable more aggressive treatments that further deplete these vital cells. The solution, he proposes, is startlingly simple: monitor the absolute lymphocyte count (ALC) via a $10 CBC test. NK cells, a subset of lymphocytes, must remain above 1,000 per microliter to maintain robust defense against cancer, infections, and sepsis. Radiation, however, often crashes this count, sometimes for over a year, leaving patients vulnerable to metastasis. A recent study highlights this “badscopal” effect, where radiation, while shrinking one tumor, may increase metastatic spread by wiping out NK cells—contrasting the long-touted “abscopal” benefit of systemic tumor reduction. Aging, viral infections, sepsis, and cancer all correlate with declining NK cell levels. Yet, Soon-Shiong emphasizes, these cells possess an innate ability to recognize and destroy transforming cells before they become cancerous. This insight shifts the paradigm from attacking disease to bolstering the body’s natural defenses. The challenge now is to rethink medical approaches. “Follow the science,” Soon-Shiong urges, advocating for data-driven strategies over entrenched agendas. By preserving NK cell counts, we may unlock the secret to long, healthy lives. This isn’t just a theory—it’s a call to transform how we fight disease.

Camus

40,290 views • 1 year ago

The system is rigged against the immune system, destroying the very cells you need to fight cancer. "We've been doing it wrong". Patrick Soon-Shiong says Chemotherapy and Radiation "Wipe out" the only cells that matter for protecting your body against cancer. "Antkiva" (AKA Bioshield) is an IL-15 based treatment that the NIH designated as the most important molecule to fight cancer, and tried to develop it for 10 years but did nothing with it. They prioritised chemotherapy as standard of care.
0:29

The system is rigged against the immune system, destroying the very cells you need to fight cancer. "We've been doing it wrong". Patrick Soon-Shiong says Chemotherapy and Radiation "Wipe out" the only cells that matter for protecting your body against cancer. "Antkiva" (AKA Bioshield) is an IL-15 based treatment that the NIH designated as the most important molecule to fight cancer, and tried to develop it for 10 years but did nothing with it. They prioritised chemotherapy as standard of care.

Humanspective

77,482 views • 10 months ago

🚨 CANCER SCAM EXPOSED: “Chemo Destroys the Very Cells That Could Save You.” 🚨 Dr. Patrick Soon-Shiong just dropped a bombshell: 🧬 “Chemo. Radiation. Even Temodol — they wipe out your natural killer cells, your body’s best defense against cancer.” 💥 One radiation dose can shut down your immune response for a YEAR. 💥 Steroids, chemo & Big Pharma’s drugs? They’re crippling your only shield. But the truth is out now—and it’s being called "Bio-Shield Therapy." A single injection that reawakens your cancer-killing cells. ✅ Patients with bladder cancer are disease-free 10+ years ✅ No toxic chemo or radiation ✅ Could treat long COVID, HIV & even sepsis ❌ Biden’s FDA blocked this. ❌ Big Pharma fought to bury it. Why? Because you can't patent the immune system God gave you. 🔥 The era of poisoning the body to “save it” is OVER. 🔥 The future of medicine is already here. 📢 FULL STORY in Cancer Decoded. Follow now to learn how we end the suffering—and save millions.
3:53

🚨 CANCER SCAM EXPOSED: “Chemo Destroys the Very Cells That Could Save You.” 🚨 Dr. Patrick Soon-Shiong just dropped a bombshell: 🧬 “Chemo. Radiation. Even Temodol — they wipe out your natural killer cells, your body’s best defense against cancer.” 💥 One radiation dose can shut down your immune response for a YEAR. 💥 Steroids, chemo & Big Pharma’s drugs? They’re crippling your only shield. But the truth is out now—and it’s being called "Bio-Shield Therapy." A single injection that reawakens your cancer-killing cells. ✅ Patients with bladder cancer are disease-free 10+ years ✅ No toxic chemo or radiation ✅ Could treat long COVID, HIV & even sepsis ❌ Biden’s FDA blocked this. ❌ Big Pharma fought to bury it. Why? Because you can't patent the immune system God gave you. 🔥 The era of poisoning the body to “save it” is OVER. 🔥 The future of medicine is already here. 📢 FULL STORY in Cancer Decoded. Follow now to learn how we end the suffering—and save millions.

Jim Ferguson

1,507,915 views • 1 year ago

Dr. Patrick Soon-Shiong was speaking pretty openly on 2Way’s Cancer Decoded about a long-standing frustration in cancer care. Standard treatments like checkpoint inhibitors, radiation, and chemo can exhaust or destroy your T-cells, the key immune fighters your body needs. But there’s real movement: late 2024, the FDA approved Anktiva (nogapendekin alfa inbakicept-pmln / N-803), an IL-15 receptor agonist. It works by expanding natural killer (NK) cells and memory CD8+ T-cells to help the immune system target hidden cancer cells more effectively, especially in BCG-unresponsive non-muscle invasive bladder cancer. He’s advocating for using low-dose traditional therapies in a smarter, immunomodulating way so the body can actually participate in the fight. This one really got to me. I’ve watched cancer hit people I care about and seen how draining the standard path can be. Hearing someone at his level talk about finally having new tools after 75 years feels like a genuine shift — hopeful, but also a reminder of how slow real change comes in medicine. Cancer treatment has followed the same heavy playbook for generations. If we can better protect and activate the immune system while treating the disease, it could mean less suffering and better real-world outcomes. What do you think — are we at the beginning of a smarter era in cancer treatment, or is it still too early to tell?
1:34

Dr. Patrick Soon-Shiong was speaking pretty openly on 2Way’s Cancer Decoded about a long-standing frustration in cancer care. Standard treatments like checkpoint inhibitors, radiation, and chemo can exhaust or destroy your T-cells, the key immune fighters your body needs. But there’s real movement: late 2024, the FDA approved Anktiva (nogapendekin alfa inbakicept-pmln / N-803), an IL-15 receptor agonist. It works by expanding natural killer (NK) cells and memory CD8+ T-cells to help the immune system target hidden cancer cells more effectively, especially in BCG-unresponsive non-muscle invasive bladder cancer. He’s advocating for using low-dose traditional therapies in a smarter, immunomodulating way so the body can actually participate in the fight. This one really got to me. I’ve watched cancer hit people I care about and seen how draining the standard path can be. Hearing someone at his level talk about finally having new tools after 75 years feels like a genuine shift — hopeful, but also a reminder of how slow real change comes in medicine. Cancer treatment has followed the same heavy playbook for generations. If we can better protect and activate the immune system while treating the disease, it could mean less suffering and better real-world outcomes. What do you think — are we at the beginning of a smarter era in cancer treatment, or is it still too early to tell?

Camus

18,305 views • 4 months ago

Dr. Patrick Soon-Shiong to Megyn Kelly: For 75 years we've treated cancer like a war—nuking tumors with poisons (chemo) and radiation while simultaneously destroying the immune system's natural killer cells and T-cells. The vicious cycle: Chemo → anemia → give Epogen → more chemo → wipe out neutrophils → give Neupogen → more chemo → destroy more lymphocytes/NK cells. FDA's gold standard? Maximum Tolerated Dose (MTD) — push the poison just below what kills the patient, measure tumor shrinkage (response rate), but ignore overall survival. Soon-Shiong: “The tumor shrinks… but the patient dies. We’re not really interested in overall survival as an endpoint. That is today’s thinking.” Megyn Kelly: “It seems to be a willing choice because we’ve gone so long without making much progress.” Clip from this 2:33 bombshell — the cancer “war” paradigm laid bare. Is MTD + response-rate obsession the reason we’re still losing the fight? Or is this the best we’ve got until something radically better arrives? Your take—seriously, drop it below.
2:33

Dr. Patrick Soon-Shiong to Megyn Kelly: For 75 years we've treated cancer like a war—nuking tumors with poisons (chemo) and radiation while simultaneously destroying the immune system's natural killer cells and T-cells. The vicious cycle: Chemo → anemia → give Epogen → more chemo → wipe out neutrophils → give Neupogen → more chemo → destroy more lymphocytes/NK cells. FDA's gold standard? Maximum Tolerated Dose (MTD) — push the poison just below what kills the patient, measure tumor shrinkage (response rate), but ignore overall survival. Soon-Shiong: “The tumor shrinks… but the patient dies. We’re not really interested in overall survival as an endpoint. That is today’s thinking.” Megyn Kelly: “It seems to be a willing choice because we’ve gone so long without making much progress.” Clip from this 2:33 bombshell — the cancer “war” paradigm laid bare. Is MTD + response-rate obsession the reason we’re still losing the fight? Or is this the best we’ve got until something radically better arrives? Your take—seriously, drop it below.

Camus

29,351 views • 6 months ago

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.
5:24

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

Camus

422,251 views • 11 months ago

Cancer - Chemotherapy wipes out the cells that "protect your body from cancer" For decades, the fundamental protocol for fighting cancer has been chemotherapy and radiation. But what if this approach inadvertently disarms the body's most powerful weapon against the very disease it seeks to destroy? Dr. Patrick Soon-Shiong explains the profound and simple truth: When a patient undergoes chemotherapy, it systematically wipes out critical components of the immune system. 1. It wipes out red blood cells, causing anemia. We have a drug for that: Epogen. 2. It wipes out neutrophils, which prevent infection. We have a drug for that: Neupogen. 3. But most critically, it decimates the lymphocytes—the NK and T cells. Here lies the devastating irony: The NK and T cells are the only cells in the human body that can recognize and kill cancer. So, within days, the standard of care eliminates the patient's primary defense system. For 35 years, we have treated the side effects of anemia and infection, all while having no therapy to restore the very cells that matter most. Dr. Soon-Shiong’s two-decade fight has been to illuminate this paradigm. We have been unintentionally protecting the patient from the consequences of our own treatments while undermining their innate ability to survive. This principle extends beyond oncology. In Long COVID, a similar pattern emerges—a viral infection that cleverly disables the T and NK cells. The lesson is clear: The future of medicine lies not in breaking the body down, but in strategically rebuilding and empowering its innate intelligence. It’s a call to move beyond managing collateral damage and to start fortifying the core of our biological defenses.
1:47

Cancer - Chemotherapy wipes out the cells that "protect your body from cancer" For decades, the fundamental protocol for fighting cancer has been chemotherapy and radiation. But what if this approach inadvertently disarms the body's most powerful weapon against the very disease it seeks to destroy? Dr. Patrick Soon-Shiong explains the profound and simple truth: When a patient undergoes chemotherapy, it systematically wipes out critical components of the immune system. 1. It wipes out red blood cells, causing anemia. We have a drug for that: Epogen. 2. It wipes out neutrophils, which prevent infection. We have a drug for that: Neupogen. 3. But most critically, it decimates the lymphocytes—the NK and T cells. Here lies the devastating irony: The NK and T cells are the only cells in the human body that can recognize and kill cancer. So, within days, the standard of care eliminates the patient's primary defense system. For 35 years, we have treated the side effects of anemia and infection, all while having no therapy to restore the very cells that matter most. Dr. Soon-Shiong’s two-decade fight has been to illuminate this paradigm. We have been unintentionally protecting the patient from the consequences of our own treatments while undermining their innate ability to survive. This principle extends beyond oncology. In Long COVID, a similar pattern emerges—a viral infection that cleverly disables the T and NK cells. The lesson is clear: The future of medicine lies not in breaking the body down, but in strategically rebuilding and empowering its innate intelligence. It’s a call to move beyond managing collateral damage and to start fortifying the core of our biological defenses.

Camus

61,712 views • 11 months ago

Dr. Patrick Soon-Shiong Exposes the Cancer Treatment Lie: "Chemo & Radiation Destroy Your Body’s Best Defense—Here’s the Breakthrough That Actually Works" For decades, the world fought cancer with two brutal weapons: chemotherapy and radiation. But what if these treatments weaken the very system designed to save you? Hidden in your body for 460 million years are natural killer cells—your immune system’s elite soldiers against cancer. Yet chemo, radiation, steroids, and even newer drugs like Temodol cripple these cells. One radiation dose can shut them down for a year—leaving patients defenseless when they need protection most. Now, the game has changed. After battling Big Pharma, FDA roadblocks, and systemic resistance, Dr. Soon-Shiong’s team has pioneered a single-injection "Bio-Shield" therapy that activates your body’s natural cancer-fighting army. The results? ✅ Bladder cancer patients disease-free for 10+ years ✅ No toxic chemo or radiation side effects ✅ Potential to treat long COVID, HIV & sepsis The Biden administration blocked this breakthrough—along with COVID treatments—but the dam has broken. The future of medicine isn’t poisoning the body to save it. It’s unleashing the power God put inside us. The full story drops in Cancer Decoded. Follow to learn how we’re ending the era of suffering—and saving millions.
3:48

Dr. Patrick Soon-Shiong Exposes the Cancer Treatment Lie: "Chemo & Radiation Destroy Your Body’s Best Defense—Here’s the Breakthrough That Actually Works" For decades, the world fought cancer with two brutal weapons: chemotherapy and radiation. But what if these treatments weaken the very system designed to save you? Hidden in your body for 460 million years are natural killer cells—your immune system’s elite soldiers against cancer. Yet chemo, radiation, steroids, and even newer drugs like Temodol cripple these cells. One radiation dose can shut them down for a year—leaving patients defenseless when they need protection most. Now, the game has changed. After battling Big Pharma, FDA roadblocks, and systemic resistance, Dr. Soon-Shiong’s team has pioneered a single-injection "Bio-Shield" therapy that activates your body’s natural cancer-fighting army. The results? ✅ Bladder cancer patients disease-free for 10+ years ✅ No toxic chemo or radiation side effects ✅ Potential to treat long COVID, HIV & sepsis The Biden administration blocked this breakthrough—along with COVID treatments—but the dam has broken. The future of medicine isn’t poisoning the body to save it. It’s unleashing the power God put inside us. The full story drops in Cancer Decoded. Follow to learn how we’re ending the era of suffering—and saving millions.

Camus

127,084 views • 1 year ago

Dr. Patrick Soon-Shiong just showed Chris Cuomo dramatic before-and-after brain scans of late-stage tumor patients who failed chemo, radiation, and surgery — achieving complete remission with ANKTIVA. No chemo. No radiation. Tumors shrinking dramatically in months. He says: “We got FDA approval to treat patients who failed everything… and they got complete remissions. It wasn’t a one-off anecdote.” ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist that activates and proliferates natural killer cells and CD8+ T-cells while avoiding regulatory T-cell suppression, turning the immune system into a targeted cancer-killing force. Clip from this 43-second segment — a potential game-changer for late-stage cases. Is ANKTIVA the breakthrough we’ve been waiting for… or do we need larger trials to confirm? Your thoughts — drop them below. Stay informed. Stay hopeful.
0:43

Dr. Patrick Soon-Shiong just showed Chris Cuomo dramatic before-and-after brain scans of late-stage tumor patients who failed chemo, radiation, and surgery — achieving complete remission with ANKTIVA. No chemo. No radiation. Tumors shrinking dramatically in months. He says: “We got FDA approval to treat patients who failed everything… and they got complete remissions. It wasn’t a one-off anecdote.” ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist that activates and proliferates natural killer cells and CD8+ T-cells while avoiding regulatory T-cell suppression, turning the immune system into a targeted cancer-killing force. Clip from this 43-second segment — a potential game-changer for late-stage cases. Is ANKTIVA the breakthrough we’ve been waiting for… or do we need larger trials to confirm? Your thoughts — drop them below. Stay informed. Stay hopeful.

Camus

282,229 views • 6 months ago

A powerful patient story from Dr. Patrick Soon-Shiong's discussion with Sean Spicer: A woman with advanced lung cancer—24 tumors (including thyroid), failed chemo/radiation, given 6-8 weeks to live—joined a trial combining Anktiva (N-803) with Keytruda. After stopping chemo, she felt immediate improvement: eating normally, no weakness, walking, gym, enjoying granddaughter, even running a festival. Scans showed shrinking tumors, thyroid gone; now 4+ years later, thriving with quality of life. Anktiva (FDA-approved 2024 for specific bladder cancer) boosts natural killer cells and T cells—key to immune attack on cancer. Soon-Shiong argues bureaucracy blocks broader access: Right to Try (advocated by Trump/Johnson) gets subverted by FDA delays/IRB hurdles; why require cancer-specific trials when NK-cell boosting helps regardless (like Epogen for anemia)? He's expanding to Canada, Europe, South Africa—where patients see responses in leukemia, etc.—while criticizing US red tape as life-costing. Inspiring remission vs. regulatory frustration: Does this highlight breakthrough potential or need for faster pathways? What's your take on access to immunotherapies like this? Real stories welcome below.
4:51

A powerful patient story from Dr. Patrick Soon-Shiong's discussion with Sean Spicer: A woman with advanced lung cancer—24 tumors (including thyroid), failed chemo/radiation, given 6-8 weeks to live—joined a trial combining Anktiva (N-803) with Keytruda. After stopping chemo, she felt immediate improvement: eating normally, no weakness, walking, gym, enjoying granddaughter, even running a festival. Scans showed shrinking tumors, thyroid gone; now 4+ years later, thriving with quality of life. Anktiva (FDA-approved 2024 for specific bladder cancer) boosts natural killer cells and T cells—key to immune attack on cancer. Soon-Shiong argues bureaucracy blocks broader access: Right to Try (advocated by Trump/Johnson) gets subverted by FDA delays/IRB hurdles; why require cancer-specific trials when NK-cell boosting helps regardless (like Epogen for anemia)? He's expanding to Canada, Europe, South Africa—where patients see responses in leukemia, etc.—while criticizing US red tape as life-costing. Inspiring remission vs. regulatory frustration: Does this highlight breakthrough potential or need for faster pathways? What's your take on access to immunotherapies like this? Real stories welcome below.

Camus

32,930 views • 8 months ago